Pharmaceuticals
Hedia appoints new CEO: Rasmus Kofoed to succeed Lars Christian Lund
COPENHAGEN, Denmark, Dec. 1, 2025 /PRNewswire/ -- Danish diabetes‑tech company Hedia is implementing a leadership change effective1 December 2025, when Rasmus Kofoed will take over as Chief Executive Officer (CEO). He succeeds Lars Christian Lund, who after approximately 2 years in the role has d...
2025-12-01 16:00
2165
The Wisdom Derived from the Great Migration: Hakka Medicine - The Unique "Medical Epic" of the Hakka People
HONG KONG, Dec. 1, 2025 /PRNewswire/ -- From November 23rd to 25th, the 7th World Hakka Conference was held in Meizhou,Guangdong. With the theme "Gathering Global Hakka Businesspeople to Foster High-Quality Development," the conference adhered to the principles of "openness, innovation, cooperati...
2025-12-01 15:26
2392
Ascletis Selects Its First Oral GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development
- Utilizing Ascletis' Peptide Oral Transport ENhancement Technology (POTENT), ASC37 oral tablets achieved average absolute oral bioavailability of 4.2%, approximately 9-, 30-, and 60-fold higher than semaglutide, tirzepatide, and retatrutide in the oral SNAC formulation, respectively, in head-to...
2025-11-30 18:15
3486
The Annals of Oncology Publishes Results of Phase II Study of Sacituzumab Tirumotecan Monotherapy for Urothelial Carcinoma
CHENGDU, China, Nov. 28, 2025 /PRNewswire/ -- Recently, Clinical study results from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", HKEX: 6990)'s TROP2 ADC sacituzumab tirumotecan (sac-TMT) monotherapy for advanced or metastatic urothelial carcinoma (UC) patients has been publ...
2025-11-28 12:32
3862
Once-Monthly GLP-1 RA | Gan & Lee Pharmaceuticals Initiates Phase 3 Clinical Study (GRADUAL-3) of the First Chinese Once-Monthly GLP-1 RA for Weight Management
BEIJING, Nov. 27, 2025 /PRNewswire/ -- Gan & Lee Pharmaceuticals (Gan & Lee, stock code: 603087.SH) announced the initiation of GRADUAL-3, its third large-scale phase 3 clinical study of the glucagon-like peptide-1 receptor agonist (GLP-1 RA) bofanglutide (research code: GZR18) injection in adult...
2025-11-27 16:57
3196
IASO Bio Announces BLA Approval of Fucaso (Equecabtagene Autoleucel) by the Hong Kong Department of Health for the Treatment of Relapsed or Refractory Multiple Myeloma
SHANGHAI and NANJING, China and PLEASANTON, Calif., Nov. 27, 2025 /PRNewswire/ -- IASO Biotechnology ("IASO Bio"), a commercial-stage biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of novel cell therapies and biologics for hematologic mali...
2025-11-27 13:44
2408
Prestige Biopharma and Biosidus Enter Exclusive License Agreement for Tuznue® Commercialization in Latin America
SINGAPORE, Nov. 26, 2025 /PRNewswire/ -- Prestige Biopharma, a biopharmaceutical company specializing in antibody therapeutics, today announced an exclusive license and supply agreement with Biosidus, a biotechnology company headquartered inBuenos Aires, Argentina, with decades of experience in ...
2025-11-26 09:06
2451
Innova Therapeutics to Advance Novel Cancer Treatment with Enci Therapeutics Acquisition
The acquisition of Enci Therapeutics will advance Innova Therapeutics' lead program, IVT-8086, a humanized monoclonal antibody targeting SFRP2 which is expressed in most solid and hematological cancers. IVT-8086 is the only cancer therapeutic that targets multiple cell types associated with canc...
2025-11-25 23:06
1774
Exyte completes Pharmaplan integration: A-to-Z execution in GMP facilities
* Pharmaplan fully integrated into Exyte, unifying biopharma engineering capabilities under one European organization. * Integrated setup drives strong client demand and a record order-intake level in 2025. * End-to-end EPC/EPCM delivery from feasibility to qualified handover across key lif...
2025-11-25 18:00
2278
Menarini Group Announces New Data on ELZONRIS® (tagraxofusp-erzs) to be Presented at the 67th American Society of Hematology Annual Meeting and Exposition
* Data spans five abstracts including two oral presentations with important findings for patients living with blastic plasmacytoid dendritic cell neoplasm (BPDCN) * BPDCN is a highly aggressive, orphan hematologic malignancy that primarily affects skin, bone marrow, and blood FLORENCE, Italy...
2025-11-24 23:34
2664
The Volpi Rosse Menarini: The 'Fantastic Ten' are ready for the 2025 - 2026 Season
Italian wheelchair basketball team, sponsored by Menarini, was presented to the press and public inItaly. The challenges they will be facing in the Italian Serie A and Eurocup 3 are already on the horizon FLORENCE, Italy, Nov. 24, 2025 /PRNewswire/ -- Ten international talents, differing in both...
2025-11-24 22:40
2241
Kelun-Biotech Announces Phase III Trial of Sac-TMT in Combination with KEYTRUDA® (pembrolizumab) as First-Line Treatment for PD-L1-Positive NSCLC Met Primary Endpoint
CHENGDU, China, Nov. 24, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced today that the Independent Data Monitoring Committee (IDMC) concluded that the Phase III clinical study (OptiTROP-Lung05) of the company's TROP2 ADC sacituzumab tiru...
2025-11-24 20:00
2798
Beyfortus® (nirsevimab) now available in Malaysia to protect all infants against RSV disease
* Beyfortus® (nirsevimab) is an available option designed to protect all infants – whether born full-term or pre-term, healthy or with underlying conditions – against respiratory syncytial virus (RSV), with proven high and sustained efficacy, a favourable safety profile, and real-world public h...
2025-11-24 16:55
2534
GenEditBio and ToolGen Enter Strategic Cross-License Agreement to Accelerate Development of Innovative Genome-Editing Therapeutics
* Integrates ToolGen's best-in-class CRISPR-Cas9 platform with GenEditBio's industry-leading lipid nanoparticle (LNP) delivery technology * Pursues a "once-and-done" treatment paradigm for diseases with high unmet medical needs SEOUL, South Korea and HONG KONG, Nov. 24, 2025 /PRNewswire/ -- G...
2025-11-24 08:00
2489
Exploring the Next Era of CGT and Unlocking Limitless Possibilities: The GenScript Biotech Global Forum London 2025 Wraps Up
PISCATAWAY, N.J., Nov. 22, 2025 /PRNewswire/ -- GenScript Biotech Corporation, a global leader in life sciences R&D and manufacturing services, successfully hosted the GenScript Biotech Global Forum London 2025 in the UK. This marks the Forum's second edition inEurope and the eighth consecutive G...
2025-11-22 20:28
2878
Global Health Leaders Convene in Kuala Lumpur from 25-27 November for Malaysia International Healthcare Megatrends 2025
A Major Conference on Innovation, Digital Health and Sustainable Care Systems KUALA LUMPUR, Malaysia, Nov. 22, 2025 /PRNewswire/ -- Healthcare leaders, policymakers and innovators from around the world will convene inMalaysia next week for the Malaysia International Healthcare (MIH) Megatrends 20...
2025-11-22 02:05
4858
Hong Kong hosts landmark International Genomic Medicine Symposium
300 Industry Leaders Gather to Drive Medical Innovations and Showcase Hong Kong's Strengths HONG KONG, Nov. 21, 2025 /PRNewswire/ -- The International Genomic Medicine Symposium (Symposium), jointly organised by the Hong Kong Genome Institute (HKGI), Rare Diseases International (RDI), and The La...
2025-11-21 15:49
1965
Telix Opens TMS Yokohama in Japan, Commemorative Lecture Held
MELBOURNE, Australia and KYOTO, Japan, Nov. 21, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces the official opening of Telix Manufacturing Solutions (TMS) inYokohama, Japan, the Company's first cyclotron facility in theAsia Pacific region (APAC...
2025-11-21 14:22
4112
NovaBridge's Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward
* Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring invaluable clinical development expertise to VIS-101 Program * The ability to attract seasoned ophthalmology leaders highlights the compelling opportunity ...
2025-11-21 13:46
1701
Everest Medicines Announces First Patient Dosed in a Global Multi-Center Phase I Clinical Trial of Tumor-Associated Antigen Cancer Vaccine EVM14
* The first patient had received the first dose of EVM14 injection in a global, multi-center Phase I clinical trial of Everest Medicines' Tumor-Associated Antigen (TAA) Cancer Vaccine EVM14 at NEXT Oncology Virginia in the United States, marking an important milestone in its global clinical dev...
2025-11-21 12:01
3278
Week's Top Stories
Most Reposted
Hong Leong Bank Unveils HLB opus Extended Exclusively by Private Invitation
[Picked up by 317 media titles]
2026-09-03 23:53
Agoda Named Official Travel Partner of Eurovision's Inaugural Asian Edition
[Picked up by 312 media titles]
2026-09-02 12:17
Visa Launches Enhanced A2A Protect Innovations to Help Financial Institutions Stop Fraud Before Money Leaves Accounts
[Picked up by 311 media titles]
2026-09-02 08:30Klook Takes Creator Commerce Beyond Influence With Kreator Shops
[Picked up by 307 media titles]
2026-09-01 11:00
DayOne and TNB Explore Up To 1.5 GW of On-Site Power Generation to Advance Malaysia's Energy Resilience and Digital Economy
[Picked up by 292 media titles]
2026-09-01 17:36Most Read
Klook Takes Creator Commerce Beyond Influence With Kreator Shops
2026-09-01 11:00
7380
YY Group Enters New Era as YYForce, Expanding AI, Automation and Human-Robot Workforce Strategy; Nasdaq Ticker Changes to "YFOR"
2026-09-01 04:10
7238
Agoda Named Official Travel Partner of Eurovision's Inaugural Asian Edition
2026-09-02 12:17
7009
